Cancer/testis antigen 1 (124-135)

Cancer/testis antigen 1 (124-135) is a synthetic peptide fragment derived from the well-characterized cancer/testis antigen family, specifically spanning amino acid residues 124 to 135 of the parent protein. As a member of the cancer/testis antigen group, this peptide is notable for its restricted expression pattern, being predominantly found in various tumor cells and germline tissues, but not in most normal somatic tissues. This unique expression profile has made cancer/testis antigens a focal point in tumor immunology and biomarker discovery. The 124-135 peptide fragment is frequently utilized in research settings to investigate antigenic epitopes, immune recognition mechanisms, and the molecular basis of tumor-specific immune responses, offering valuable insights for the development of diagnostic and experimental immunotherapeutic strategies.

Epitope mapping: Researchers employ the 124-135 peptide fragment in the systematic identification and characterization of T-cell and B-cell epitopes within cancer/testis antigens. By using this defined sequence in immunoassays or cellular activation studies, scientists can delineate the minimal regions necessary for immune recognition, facilitating the understanding of antigen-specific immune responses. Such epitope mapping is crucial for uncovering the molecular determinants of immunogenicity and for guiding the rational design of targeted immunological reagents.

Immunogenicity studies: The peptide serves as a precise tool in evaluating the immunogenic potential of cancer/testis antigens in various experimental models. By incorporating the 124-135 sequence into in vitro or ex vivo assays, investigators can assess T-cell activation, cytokine production, and the specificity of immune effector functions. These studies are instrumental in dissecting the mechanisms underlying tumor antigen recognition, informing the optimization of antigen constructs for research applications in cellular immunology.

Peptide-based assay development: The defined sequence of this antigenic peptide is leveraged in the development of sensitive and specific immunoassays, such as ELISPOT, ELISA, or flow cytometry-based detection platforms. Incorporation of the 124-135 fragment enables accurate quantification of antigen-specific lymphocyte populations or antibody responses in biological samples. Such assay systems are widely utilized in basic immunology research, vaccine evaluation models, and the monitoring of antigen-specific immune reactivity in experimental settings.

Synthetic peptide synthesis validation: The Cancer/testis antigen 1 (124-135) fragment is frequently used as a reference or control in the synthesis and quality assessment of peptide libraries. Its well-defined sequence and immunological relevance make it a valuable standard for validating peptide synthesis protocols, assessing purity, and benchmarking analytical methodologies such as HPLC or mass spectrometry. This supports the reliability and reproducibility of peptide-based research tools in laboratory workflows.

Antigen presentation and MHC binding studies: The peptide is instrumental in exploring the molecular interactions between tumor-associated antigens and major histocompatibility complex (MHC) molecules. By studying its binding affinity and presentation by various MHC alleles, researchers gain critical insights into antigen processing, presentation pathways, and determinants of T-cell recognition. These investigations contribute to a deeper understanding of tumor immunology and the design of experimental models for antigen presentation research.

1. The effect of sex on immune responses to a homocitrullinated peptide in the DR4-transgenic mouse model of Rheumatoid Arthritis

2. Myotropic activity and immunolocalization of selected neuropeptides of the burying beetle Nicrophorus vespilloides (Coleoptera: Silphidae)

3. Cell-based adhesion assays for isolation of snake venom’s integrin antagonists

4. cRGD-functionalized, DOX-conjugated, and 64Cu-labeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging

5. Genetic, cellular, and structural characterization of the membrane potential-dependent cell-penetrating peptide translocation pore